Clinical trial
A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
NCT05032066 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Amgen
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 20, 2022
- Completion date
- January 2, 2025
- Enrollment
- 153 (actual)
- Sites
- 82
Conditions
As the registry lists them; a condition with its own page is linked.